List of Excipients in Branded Drug SYNJARDY

Last updated: July 30, 2026

Excipient Strategy and Commercial Opportunities for SYNJARDY (empagliflozin/metformin HCl)

Executive summary: SYNJARDY (empagliflozin/metformin HCl) combines an SGLT2 inhibitor with metformin for type 2 diabetes. Commercial opportunities concentrate on (1) excipient systems that support high-throughput manufacturing and robust tablet performance, (2) supply continuity and cost optimization in metformin and empagliflozin dosage forms, and (3) lifecycle extensions that strengthen differentiation versus generics using excipient-driven formulation IP and line extensions (dose, strength, and patient-centric release targets where permitted). Near-term revenue exposure is driven by patent and regulatory readiness for generic entry of the fixed-dose combination and by the cadence of FDA ANDA approvals in comparable empagliflozin/metformin strengths.

---

What excipient strategy matters for SYNJARDY tablets (empagliflozin + metformin) in manufacturing?

Short answer: Excipients determine mechanical strength, dissolution kinetics, stability under humidity, and compatibility with the two actives, while enabling scalable tableting and packaging for large commercial volume.

Key formulation constraints for this drug combination

SYNJARDY tablets have two distinct functional “needs”:

• Empagliflozin (SGLT2 inhibitor): typically requires excipient environments that minimize chemical degradation and ensure consistent dissolution performance at low milligram scale.
• Metformin HCl: tends to be more hygroscopic and can be sensitive to moisture-driven stability changes; it also drives tablet compressibility and dissolution behavior.

Excipient workstreams that correlate with commercial execution

The high-value excipient strategy for a fixed-dose combination tends to fall into these buckets:

1. Tablet mechanical robustness

   • Binder and lubricant selection to stabilize hardness and reduce capping or lamination in fast presses.
   • Glidant selection to control die fill and content uniformity across scale-up lots.

2. Humidity and chemical stability

   • Moisture management via film coat and anti-moisture excipients.
   • Internal desiccant systems or optimized pore-formers where applicable in solid dosage.

3. Dissolution and bioavailability consistency

   • Disintegrant systems tuned to avoid slow-gelling or agglomeration behavior.
   • Control of surface wetting to reduce variability between batches and lots.

4. Compatibility and process robustness

   • Direct compression feasibility vs wet granulation tradeoffs.
   • Solvent system compatibility (if granulation uses aqueous ethanol or other systems).
   • Avoiding excipients that catalyze oxidative degradation or interact with metformin salt form.

High-impact excipient design choices (typical in SGLT2/metformin combos)

Below is a business-oriented excipient “map” that is used to de-risk manufacturing and strengthen differentiation in lifecycle programs.

Tablet performance target	Excipient lever	Why it matters commercially
Hardness and friability	Binders (polymeric or microcrystalline)	Reduces returns, improves shelf durability, supports lower packaging spend per tablet
Content uniformity	Glidants and flow enhancers	Lowers rejection rates in CMOs and allows higher line speeds
Disintegration time	Superdisintegrants (crosslinked polymers)	Improves robustness of dissolution specs across humidity swings
Dissolution similarity	Wetting agents and solubilizers	Reduces risk of ANDA dissolution non-equivalence and delays
Moisture stability	Film coat composition and moisture-barrier excipients	Extends shelf life, reduces stability failures and requalification costs
Process efficiency	Lubricants and granulation aids	Enables faster manufacturing cycles and tighter cost of goods

---

Which excipients support stability and shelf-life for SYNJARDY, especially under real-world humidity?

Short answer: Moisture barrier excipient selection plus a robust coating system and internal tablet water management are the primary levers for shelf-life reliability.

Shelf-life drivers in fixed-dose combinations

For metformin-containing tablets, moisture uptake can change tablet microstructure, shift dissolution curves, and increase risk of degradation. For empagliflozin, chemical stability and dissolution reproducibility remain sensitive to storage conditions.

Commercial outcome: stable lots reduce stability retesting cadence, prevent lot disposition costs, and protect market supply during peak seasons.

Coating and packaging as part of the excipient strategy

While excipients include tablet interior ingredients, the practical shelf-life system also includes:

• Film coat barrier performance (polymer selection, plasticizer and opacifier composition)
• Opacifier needs to maintain visual uniformity without adding permeability
• Packaging pairing (high barrier bottles or blister systems) as an “excipient companion” in the commercial shelf-life plan

---

What excipient IP opportunities exist to differentiate SYNJARDY vs generics?

Short answer: Excipient-driven formulation IP can provide a defensible barrier if it is tied to measurable formulation outcomes (dissolution, stability, bioavailability, or process performance) rather than generic “lists” of inert ingredients.

Where excipient differentiation works best

Excipient IP tends to be most defensible when it covers:

• Specific combinations of excipients at defined ratios
• Defined process parameters (e.g., granulation endpoints, blending times) linked to final quality attributes
• A clear functional claim tied to dissolution kinetics or stability under ICH conditions

Lifecycle pathways that align with excipient differentiation

If SYNJARDY’s fixed-dose strengths are being challenged, the highest-execution excipient opportunities are typically:

1. New strength launch with a distinct formulation system
2. Line extension to address stability or dissolution variability
3. Coating and moisture-management upgrades
4. Alternative manufacturing process routes (dry granulation vs wet granulation, or direct compression with modified excipient blends)

---

When does SYNJARDY lose exclusivity, and how does that affect excipient commercialization choices?

Short answer: Generic and biosimilar timelines are driven by patent expiration and regulatory exclusivity, which changes the ROI of formulation upgrades and excipient re-platforming.

Exclusivity and patent strategy impact on excipient spend

• Before a major exclusivity window closes, excipient upgrades are primarily justified for manufacturing cost-down, yield improvements, and stability margin.
• After exclusivity loosens, excipient work shifts toward differentiation claims (measurable performance) and risk reduction for ANDA bioequivalence non-equivalence threats (especially dissolution specification).

---

How many patents cover SYNJARDY excipient-relevant formulation or manufacturing, and who holds them?

Short answer: The SYNJARDY fixed-dose combination estate includes composition and method patents. Excipient-relevant coverage usually sits in composition-of-matter and formulation-process patents that define specific ingredient systems and manufacturing routes.

Patent estate mapping needed for actionability

To assess excipient IP and commercial barriers, you typically segment into:

• Formulation composition patents (tablet composition, excipient ratios, and ranges)
• Manufacturing method patents (granulation method, mixing/blending, drying)
• Coating and stability patents (film coat systems and moisture barrier claims)
• Method-of-use patents (less excipient-relevant but determines exclusivity posture)

Business use: this segmentation supports a licensing plan that can target formulation-specific assets rather than broad platform IP.

---

What is the Orange Book status of SYNJARDY, and what does it imply for formulation changes?

Short answer: The Orange Book governs the regulatory exclusivity map used by ANDA filers to time Paragraph IV challenges. Excipient changes that alter formulation composition can impact ANDA equivalence strategy and may require new stability packages if the product is repositioned.

Orange Book-driven decisions for excipient strategy

• If the listed patents are composition or method-of-use, formulation excipient changes may not avoid exposure but can improve manufacturing economics.
• If a formulation is near the end of exclusivity, excipient strategy should focus on cost of goods and robustness rather than expecting significant incremental market exclusivity.

---

Which companies are challenging SYNJARDY, and what excipient-related risks appear in those ANDA pathways?

Short answer: ANDA challengers typically focus on bioequivalence and dissolution similarity, so excipient-driven dissolution and stability targets become the risk front.

ANDA execution risk factors that excipient strategy can influence

• Failure to match dissolution profile due to disintegrant choice and wetting behavior
• Batch-to-batch variation if flow and blending are not controlled via excipient system
• Stability shortfalls if the moisture management system diverges from the reference

Practical commercial impact

Where competitors are close behind, a manufacturer’s excipient plan must include:

• Tight incoming raw material controls (excipient grade and moisture)
• Defined moisture limits for storage and manufacturing
• Dissolution and stability trending that protects against market interruptions

---

How does SYNJARDY compare with empagliflozin/metformin competitors on excipient and formulation differentiation?

Short answer: Differentiation is generally not about the active ingredient identity but about the formulation system that controls dissolution, stability, and manufacturability. Competitors with similar actives may still diverge on excipient systems that affect dissolution similarity.

What to benchmark in competitor products

For commercial intelligence, compare:

• Tablet hardness, friability, and disintegration time
• Dissolution profile (in multiple media)
• Stability performance at stress conditions
• Manufacturing process route disclosed in patents (granulation vs direct compression) and correlating excipient choices

---

What commercial opportunities exist from excipient platform reuse across SGLT2/metformin brands?

Short answer: The strongest opportunity is scaling an excipient platform across adjacent metabolic and SGLT2 combination products to reduce development and tech-transfer cost while maintaining quality attributes.

Where excipient reuse typically wins

• Same tablet geometry and coating system across multiple strengths
• Shared disintegrant and lubricant strategy tuned to metformin salt performance
• Shared humidity barrier packaging approach for shelf-life continuity

Execution levers for cost-down

• Bulk purchasing contracts for high-volume excipients
• Converged supplier qualification packages
• Standardized blending and granulation control templates for CMOs

---

What excipient strategy reduces COGS for SYNJARDY without raising regulatory or quality risk?

Short answer: Cost-down prioritizes substituting lower-cost excipients where performance is preserved, reducing process steps, and improving yields while keeping dissolution and stability within specification.

Cost-of-goods levers tied to excipients

• Fewer process steps: enabling direct compression or shortened granulation cycles if feasible
• Lower overages: improved content uniformity can cut economic overage
• Higher yield: better flow reduces losses at blending and tablet compression
• Lower packaging spend: shelf-life margin can reduce retesting and change packaging spec selection

---

Key Takeaways

• Excipient strategy for SYNJARDY is primarily about moisture stability, dissolution robustness, and scalable manufacturability for a fixed-dose tablet.
• Commercial differentiation against generics is most defensible when excipient systems are tied to measurable functional outcomes (dissolution, stability, and process performance) in formulation-specific IP.
• Near-term commercialization favors excipient-driven cost of goods and supply continuity; lifecycle differentiation efforts shift toward measurable performance if exclusivity is nearing end.
• Excipients influence ANDA dissolution and stability risks, making them central to competitive defense even when active ingredients are the same.

---

FAQs

1) What tablet excipients most affect dissolution similarity for empagliflozin/metformin combinations?

Disintegrant selection (type and grade), wetting behavior, and the internal moisture environment are typically the highest sensitivity levers for dissolution similarity.

2) How do film-coat moisture barriers change stability outcomes for metformin-containing tablets?

Barrier polymer systems and permeability control reduce moisture ingress, which stabilizes tablet microstructure and supports consistent dissolution.

3) Can changing excipients trigger new regulatory filings for SYNJARDY?

Formulation changes generally require regulatory comparability under change control frameworks; the risk depends on the magnitude of changes and the impact on quality attributes.

4) What manufacturing excipient choices improve content uniformity on high-speed tablet presses?

Flow enhancers and glidants that stabilize die fill, paired with controlled blending and lubricant strategy to reduce segregation risk.

5) What is the best excipient strategy to reduce rejection rates during scale-up?

Use an excipient system that improves flow and compressibility while keeping dissolution and hardness within established control strategy targets, backed by real-time in-process monitoring.

---

References

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
2. EMA. “Guideline on the Investigation of Bioequivalence.” European Medicines Agency.
3. ICH. “ICH Q1A(R2): Stability Testing of New Drug Substances and Products.” International Council for Harmonisation.
4. ICH. “ICH Q8(R2): Pharmaceutical Development.” International Council for Harmonisation.
5. ICH. “ICH Q9: Quality Risk Management.” International Council for Harmonisation.